GV led a $58.5m round for the heart disease drug developer, which is advancing research conducted at Harvard University and Broad Institute and has a partnership in place with Harvard spinout Beam Therapeutics.
Verve Therapeutics, a US-based gene editing technology provider based on research at Harvard University and Broad Institute, secured $58.5m on Tuesday in a series A round led by GV, a corporate venturing subsidiary of conglomerate Alphabet.
F-Prime Capital, a subsidiary of investment and financial services group Fidelity, also participated in the round, as did venture capital firms Arch Venture Partners and Biomatics Capital.
Verve is using genetic analysis and gene editing to developing therapies capable of making edits…
